SG10201808738WA - Fusokines involving cytokines with strongly reduced receptor binding affinities - Google Patents

Fusokines involving cytokines with strongly reduced receptor binding affinities

Info

Publication number
SG10201808738WA
SG10201808738WA SG10201808738WA SG10201808738WA SG10201808738WA SG 10201808738W A SG10201808738W A SG 10201808738WA SG 10201808738W A SG10201808738W A SG 10201808738WA SG 10201808738W A SG10201808738W A SG 10201808738WA SG 10201808738W A SG10201808738W A SG 10201808738WA
Authority
SG
Singapore
Prior art keywords
fusokines
strongly reduced
receptor binding
binding affinities
cytokines
Prior art date
Application number
SG10201808738WA
Inventor
Jan Tavernier
Jennyfer Bultinck
Sarah Gerlo
Gilles Uzé
Franciane Paul
Yann Bordat
Original Assignee
Vib Vzw
Univ Gent
Centre Nat Rech Scient
Univ Montpellier
Centre Hospitalier Regional Univ De Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Univ Gent, Centre Nat Rech Scient, Univ Montpellier, Centre Hospitalier Regional Univ De Montpellier filed Critical Vib Vzw
Publication of SG10201808738WA publication Critical patent/SG10201808738WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Abstract

FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases. (No drawing to be published)
SG10201808738WA 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities SG10201808738WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306034 2013-07-18

Publications (1)

Publication Number Publication Date
SG10201808738WA true SG10201808738WA (en) 2018-11-29

Family

ID=48906191

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201600163VA SG11201600163VA (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities
SG10201808738WA SG10201808738WA (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201600163VA SG11201600163VA (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities

Country Status (15)

Country Link
US (3) US10640542B2 (en)
EP (2) EP3022305B1 (en)
JP (2) JP6580037B2 (en)
KR (1) KR102322510B1 (en)
CN (2) CN105705641B (en)
AU (2) AU2014292371B2 (en)
BR (1) BR112016001036B1 (en)
CA (1) CA2917937C (en)
DK (1) DK3299466T3 (en)
ES (2) ES2757501T3 (en)
HK (1) HK1252831A1 (en)
IL (1) IL243451B (en)
MX (1) MX2016000611A (en)
SG (2) SG11201600163VA (en)
WO (1) WO2015007536A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3003969A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
CA3013554A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Targeted therapeutic agents and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
CA3023881A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
EP3454887B1 (en) 2016-05-13 2021-01-20 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
JP2020506727A (en) 2017-02-06 2020-03-05 オリオンズ バイオサイエンス エヌブイ Targeted chimeric proteins and uses thereof
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
US11246911B2 (en) 2017-02-07 2022-02-15 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
CN111511763A (en) 2017-08-09 2020-08-07 奥里尼斯生物科学有限公司 CD8 binding agents
EP3664829A4 (en) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. Pd-1 and pd-l1 binding agents
WO2019152979A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
US11440943B2 (en) 2019-03-28 2022-09-13 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
CN117241813A (en) * 2021-04-30 2023-12-15 卡利威尔免疫治疗公司 Oncolytic viruses for modified MHC expression

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002754A1 (en) 1989-08-22 1991-03-07 Immunex Corporation Fusion proteins comprising gm-csf and il-3
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
EP1200479B1 (en) * 1999-08-09 2006-02-01 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20020177571A1 (en) * 2000-11-29 2002-11-28 Gordon Erlinda M. Targeted vectors for cancer immunotherapy
CN1168740C (en) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 Cell factor gene modified antigen presentation cell/tumor cell conjugate, its preparatino and use
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
DE602004031341D1 (en) * 2003-07-21 2011-03-24 Transgene Sa MULTIFUNCTIONAL CYTOKINE
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
WO2006053883A1 (en) 2004-11-18 2006-05-26 Vib Vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
US7947265B2 (en) 2006-08-02 2011-05-24 Mcgill University Fusion proteins and methods for modulation of immune response
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
EP2853267B1 (en) 2007-09-21 2016-12-07 The Regents of the University of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
WO2010036918A2 (en) 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
US20110294983A1 (en) 2008-12-08 2011-12-01 Complix Nv Single-chain antiparallel coiled coil proteins
KR101588598B1 (en) 2009-08-17 2016-01-29 로슈 글리카트 아게 Targeted immunoconjugates
CN102497885A (en) 2009-09-10 2012-06-13 赛托斯生物技术公司 Use of interleukin-1 beta mutein conjugates in the treatment of diabetes
AU2010313112B2 (en) * 2009-11-02 2014-06-26 The Regents Of The University Of California Vault complexes for cytokine delivery
KR101589951B1 (en) * 2009-12-23 2016-01-29 그래댈리스, 인코포레이티드 Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
EP2560671B1 (en) * 2010-04-22 2014-09-24 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. High affinity leptins and leptin antagonists
CN102372780A (en) * 2010-08-23 2012-03-14 上海市计划生育科学研究所 Preparation method and application of anti-human chorionic gonadotropin (hCG) antibody-interleukin 2 (IL2) fusion protein
EP2718457A4 (en) 2011-06-06 2014-12-24 Immungene Inc Engineered antibody-tnfsf member ligand fusion molecules
EA034989B1 (en) 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Polypeptide construct for use in treating cancer comprising attenuated alpha interferon
KR102050119B1 (en) * 2012-01-20 2019-11-28 브이아이비 브이지더블유 Targeted mutant alpha-helical bundle cytokines
HUE049945T2 (en) 2012-03-03 2020-11-30 Immungene Inc Engineered antibody-interferon mutant fusion molecules
JP6730271B2 (en) * 2014-10-29 2020-07-29 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Interferon α2B variant

Also Published As

Publication number Publication date
IL243451B (en) 2019-10-31
CA2917937C (en) 2022-11-01
WO2015007536A2 (en) 2015-01-22
MX2016000611A (en) 2016-09-29
CA2917937A1 (en) 2015-01-22
CN110835376B (en) 2023-08-04
JP2020002155A (en) 2020-01-09
CN105705641B (en) 2021-07-13
EP3299466A1 (en) 2018-03-28
WO2015007536A3 (en) 2015-03-19
EP3299466B1 (en) 2019-09-11
KR20160108291A (en) 2016-09-19
JP6853317B2 (en) 2021-03-31
ES2757501T3 (en) 2020-04-29
US11358997B2 (en) 2022-06-14
KR102322510B1 (en) 2021-11-08
CN110835376A (en) 2020-02-25
IL243451A0 (en) 2016-03-31
DK3299466T3 (en) 2019-11-18
EP3022305B1 (en) 2017-11-01
AU2014292371A1 (en) 2016-02-04
CN105705641A (en) 2016-06-22
US10640542B2 (en) 2020-05-05
JP2016525516A (en) 2016-08-25
AU2018203868B2 (en) 2019-12-05
BR112016001036B1 (en) 2023-02-23
SG11201600163VA (en) 2016-02-26
US20230054612A1 (en) 2023-02-23
BR112016001036A2 (en) 2017-10-24
US20190010199A1 (en) 2019-01-10
JP6580037B2 (en) 2019-09-25
HK1252831A1 (en) 2019-06-06
ES2657060T3 (en) 2018-03-01
AU2014292371B2 (en) 2018-03-29
US20180155404A1 (en) 2018-06-07
AU2018203868A1 (en) 2018-06-21
EP3022305A2 (en) 2016-05-25

Similar Documents

Publication Publication Date Title
SG10201808738WA (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
MX2013005793A (en) Low affinity blood brain barrier receptor antibodies and uses therefor.
MX2016010953A (en) Multimeric fc proteins.
MX343659B (en) Fc RECEPTOR BINDING PROTEINS.
MX2017007491A (en) Blood brain barrier receptor antibodies and methods of use.
PH12016500123A1 (en) Therapeutic fusion protein
MX2017014397A (en) Anti-fcrn antibodies.
TR201903312T4 (en) Methods to reduce asthma exacerbation rates using benralizumab.
PL3200822T3 (en) Binding molecules, especially antibodies, binding to l1cam (cd171)
PH12016500753A1 (en) Antibodies specific to fcrn
EP3297662A4 (en) Antibodies that bind to axl proteins
NZ718044A (en) Fusion protein
MX2015013066A (en) Therapeutic uses for vegfr1 antibodies.
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
EP3551228A4 (en) Antibodies to human alpha-synuclein
EP3339320A4 (en) Chimeric antibody receptor to which anti-cotinine antibody is linked, and use thereof
DK3020732T3 (en) Immunoglobulin-Fc conjugate which retains the binding affinity of the immunoglobulin-Fc fragment to FcRn
PH12016500826A1 (en) Anti-ccl17 antibodies
MX2016014416A (en) Anti-her3 antibodies binding to the beta-hairpin of her3.
MX2017007747A (en) Antibodies for il-17c.
EP3297663A4 (en) Antibodies that bind to axl proteins
MX2016001691A (en) Bag3 receptor binding molecules for use as a medicament.
WO2014137229A3 (en) Neural regeneration peptides and uses therefor